达格列净联合氯沙坦而非奥美沙坦对实验性Alport综合征具有附加保护作用

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of pharmacological sciences Pub Date : 2025-09-20 DOI:10.1016/j.jphs.2025.09.008

Jun Horizono , Keito Mizumoto , Mary Ann Suico , Shota Kaseda , Yuya Sannomiya , Haruki Tsuhako , Aimi Owaki , Ryoichi Sato , Masahiro Shiraga , Riko Kato , Ryo Kumabe , Tsuyoshi Shuto , Hirofumi Kai

{"title":"达格列净联合氯沙坦而非奥美沙坦对实验性Alport综合征具有附加保护作用","authors":"Jun Horizono , Keito Mizumoto , Mary Ann Suico , Shota Kaseda , Yuya Sannomiya , Haruki Tsuhako , Aimi Owaki , Ryoichi Sato , Masahiro Shiraga , Riko Kato , Ryo Kumabe , Tsuyoshi Shuto , Hirofumi Kai","doi":"10.1016/j.jphs.2025.09.008","DOIUrl":null,"url":null,"abstract":"<div><div>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and angiotensin receptor blockers (ARBs) each have renoprotective effects in chronic kidney diseases, including Alport syndrome. Here, we investigated the combination of SGLT2i dapagliflozin and ARBs with different antiproteinuric strength - losartan (weak) and olmesartan (strong) - in <em>Col4a5</em> G5X Alport mice. Dapagliflozin enhanced the renoprotective effect of losartan but not of olmesartan. Olmesartan alone suppressed the decline in renal function and prolonged survival similarly to losartan plus dapagliflozin. These findings suggest that the add-on effectiveness of dapagliflozin varies depending on the ARB, and that their combination needs careful evaluation for maximum benefit.</div></div>","PeriodicalId":16786,"journal":{"name":"Journal of pharmacological sciences","volume":"159 4","pages":"Pages 252-255"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome\",\"authors\":\"Jun Horizono , Keito Mizumoto , Mary Ann Suico , Shota Kaseda , Yuya Sannomiya , Haruki Tsuhako , Aimi Owaki , Ryoichi Sato , Masahiro Shiraga , Riko Kato , Ryo Kumabe , Tsuyoshi Shuto , Hirofumi Kai\",\"doi\":\"10.1016/j.jphs.2025.09.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and angiotensin receptor blockers (ARBs) each have renoprotective effects in chronic kidney diseases, including Alport syndrome. Here, we investigated the combination of SGLT2i dapagliflozin and ARBs with different antiproteinuric strength - losartan (weak) and olmesartan (strong) - in <em>Col4a5</em> G5X Alport mice. Dapagliflozin enhanced the renoprotective effect of losartan but not of olmesartan. Olmesartan alone suppressed the decline in renal function and prolonged survival similarly to losartan plus dapagliflozin. These findings suggest that the add-on effectiveness of dapagliflozin varies depending on the ARB, and that their combination needs careful evaluation for maximum benefit.</div></div>\",\"PeriodicalId\":16786,\"journal\":{\"name\":\"Journal of pharmacological sciences\",\"volume\":\"159 4\",\"pages\":\"Pages 252-255\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmacological sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1347861325000945\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1347861325000945","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）和血管紧张素受体阻滞剂（ARBs）在慢性肾脏疾病（包括Alport综合征）中均具有肾保护作用。在Col4a5 G5X Alport小鼠中，我们研究了SGLT2i dapag列净和具有不同抗蛋白尿强度的arb（氯沙坦（弱）和奥美沙坦（强））的联合使用。达格列净对氯沙坦的肾保护作用有增强作用，而对奥美沙坦没有增强作用。与氯沙坦加达格列净类似，单用奥美沙坦抑制肾功能下降并延长生存期。这些发现表明，达格列净的附加效果因ARB而异，它们的组合需要仔细评估以获得最大的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and angiotensin receptor blockers (ARBs) each have renoprotective effects in chronic kidney diseases, including Alport syndrome. Here, we investigated the combination of SGLT2i dapagliflozin and ARBs with different antiproteinuric strength - losartan (weak) and olmesartan (strong) - in Col4a5 G5X Alport mice. Dapagliflozin enhanced the renoprotective effect of losartan but not of olmesartan. Olmesartan alone suppressed the decline in renal function and prolonged survival similarly to losartan plus dapagliflozin. These findings suggest that the add-on effectiveness of dapagliflozin varies depending on the ARB, and that their combination needs careful evaluation for maximum benefit.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of pharmacological sciences 医学-药学

CiteScore

6.20

自引率

2.90%

发文量

104

审稿时长

31 days

期刊介绍： Journal of Pharmacological Sciences (JPS) is an international open access journal intended for the advancement of pharmacological sciences in the world. The Journal welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology for publication as Reviews, Full Papers or Short Communications. Short Communications are short research article intended to provide novel and exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanism and dose-response determinations are not acceptable and will be rejected without peer review. The ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.